Silence Therapeutics PLC IP update (5522K)
10 July 2017 - 4:41PM
UK Regulatory
TIDMSLN
RNS Number : 5522K
Silence Therapeutics PLC
10 July 2017
IP Update
10 July 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, notes Alnylam Pharmaceutical's press release of July
7, 2017 which stated that "Alnylam and Sanofi Genzyme Initiate
ATLAS Phase 3 Program with Investigational RNAi Therapeutic
Fitusiran in Patients with Hemophilia A and B with or without
Inhibitors ".
On July 3, 2017, Silence referenced Fitusiran within a list of
Alnylam products that are being included within a claim issued in
the UK courts relating to Silence's entitlement to supplementary
protection certificates (SPC's) that extend European patent
protection on those products.
Silence further notes that on November 14, 2016, Alnylam also
announced that "Sanofi Genzyme elected to opt in to co-develop
(through Sanofi R&D) and co-commercialize Fitusiran, an
investigational RNAi therapeutic for the treatment of hemophilia
and rare bleeding disorders (RBD), in the United States, Canada and
Western Europe." This co-development includes a $25 million
milestone payable by Sanofi Genzyme upon the initiation of the
first global Phase 3 clinical trial for Fitusiran as well as
further payments totalling up to $75 million upon the achievement
of development and regulatory milestones for Fitusiran.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics,
commented:
"We are delighted on behalf of patients with hemophilia A and B
to hear this encouraging development, further highlighting the
importance of siRNA medicines, and reiterate as stated in our press
release on 30 May, 2017, that we consider potential licences under
our patent estate could have a significant financial effect
relative to the current market capitalisation of Silence."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser Tel: +44 (0)20
and Broker) 7418 8900
James Steel/Oliver Jackson
Media Enquiries: Tel: +44 (0)
FTI Consulting 20 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAKXEFLEXEEF
(END) Dow Jones Newswires
July 10, 2017 02:41 ET (06:41 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024